Skip to main content
Recent Quotes
My Watchlist
Indicators
Markets
Stocks
ETFs
Tools
Markets:
Overview
News
Currencies
International
Treasuries

United Therapeutics Corporation - Common Stock (NQ:UTHR)

418.19 -0.39 (-0.09%)
Streaming Delayed Price Updated: 11:52 AM EDT, Oct 27, 2025 Add to My Watchlist
Quote
Overview Detailed Quote Charting Historical Prices
News
All News News Headlines Press Releases
Research
Quarterly Reports Insider Filings Other Filings

Headline News about United Therapeutics Corporation - Common Stock

< Previous 1 2 3 4 5 6 7 8 9 10 Next >
If You Invested $100 In United Therapeutics Stock 15 Years Ago, You Would Have This Much Today
 
Via Benzinga
United Therapeutics Forges Ahead with Share Repurchases, Not Dividends, Following July 2025 Volume Surge
In a financial landscape often fixated on consistent dividend payouts, United Therapeutics Corporation (NASDAQ: UTHR) stands out with a distinct capital allocation strategy. Contrary to market... 
Via MarketMinute
Topics Retirement
United Therapeutics Corp (NASDAQ:UTHR) Meets Key Peter Lynch Investment Criteria
United Therapeutics (UTHR) aligns with Peter Lynch's investment strategy, showing strong earnings growth, a fair PEG ratio, and a debt-free balance sheet for long-term value. 
Via Chartmill
United Therapeutics Corp (NASDAQ:UTHR) Emerges as a Prime Value Investment Candidate
United Therapeutics (UTHR) is a strong value stock with a low P/E ratio, zero debt, high profitability, and solid growth, making it an undervalued biotech pick. 
Via Chartmill
MannKind Lands A Price-Target Hike After Partner United Therapeutics Reports Strong Lung Drug Trial Results
Via Stocktwits
This Pharma Stock Soared 36% Today And Drew Price Target Hikes From Wall Street – More Details Inside
Via Stocktwits
MannKind, United Therapeutics Expand Agreement To Develop A Second Investigational Molecule Together
Via Stocktwits
1 Value Stock for Long-Term Investors and 2 Facing Headwinds
Value stocks typically trade at discounts to the broader market, offering patient investors the opportunity to buy businesses when they’re out of favor. The key risk, however, is that these stocks are... 
Via StockStory
2 Growth Stocks with All-Star Potential and 1 Facing Headwinds
Growth is oxygen. But when it evaporates, the consequences can be severe - ask anyone who bought Cisco in the Dot-Com Bubble or newer investors who lived through the 2020 to 2022 COVID cycle. 
Via StockStory
This United Therapeutics Analyst Begins Coverage On A Bullish Note; Here Are Top 5 Initiations For Friday
Top Wall Street analysts changed their outlook on these top names. For a complete view of all analyst rating changes, including upgrades, downgrades and initiations, please see our analyst ratings... 
Via Benzinga
1 Momentum Stock to Target This Week and 2 We Brush Off
The stocks featured in this article have all approached their 52-week highs. When these price levels hit, it typically signals strong business execution, positive market sentiment, or significant... 
Via StockStory
3 Big Reasons to Love United Therapeutics (UTHR)
United Therapeutics currently trades at $412.41 and has been a dream stock for shareholders. It’s returned 308% since September 2020, tripling the S&P 500’s 103% gain. The company has also beaten the... 
Via StockStory
Topics Stocks
United Therapeutics Corp (NASDAQ:UTHR) Emerges as a Top Peter Lynch-Style GARP Investment
United Therapeutics (UTHR) aligns with Peter Lynch's GARP strategy, featuring strong EPS growth, a PEG below 1, zero debt, and robust financial health. 
Via Chartmill
United Therapeutics Price Strength Rating Jumps After Its Stock Soared 33% Last Week On Positive Drug Test Results
United Therapeutics also boasts a terrific 96 Composite Rating. The Composite score combines five separate proprietary ratings into one. 
Via Investor's Business Daily
Topics ETFs
Wayfair, United Therapeutics, And Ciena Are Among The Top 10 Large-Cap Gainers Last Week (July 14-July 18): Are The Others In Your Portfolio?
These ten large-cap stocks were top performers last week. Are they a part of your portfolio? 
Via Benzinga
United Therapeutics Corp (NASDAQ:UTHR): A Prime Value Investing Candidate with Strong Fundamentals
United Therapeutics (UTHR) is a strong value investing candidate with low P/E, zero debt, high profitability, and excellent financial health, offering a solid margin of safety. 
Via Chartmill
Here are the top movers in Tuesday's session.
Here are the top movers in Tuesday's session, showcasing the stocks with significant price changes. 
Via Chartmill
12 Health Care Stocks Moving In Tuesday's Intraday Session
 
Via Benzinga
Dow Tumbles Over 1%; Nio Shares Edge Lower After Q2 Results
 
Via Benzinga
Topics Stocks
Top movers analysis in the middle of the day on 2025-09-02: top gainers and losers in today's session.
Keep an eye on the top gainers and losers in Tuesday's session, as they reflect the most notable price movements. 
Via Chartmill
Why Is United Therapeutics Stock Rallying On Tuesday?
United Therapeutics' Tyvaso showed significant lung function improvement in IPF patients, with plans to seek FDA approval for expanded use. 
Via Benzinga
Air Lease, Ionis Pharmaceuticals, Arrowhead Pharmaceuticals And Other Big Stocks Moving Higher On Tuesday
 
Via Benzinga
There are notable gap-ups and gap-downs in today's session.
The session on Tuesday is off to an intriguing start with several stocks showing significant price gaps. Let's examine the gap up and gap down stocks in today's session. 
Via Chartmill
Why United Therapeutics Just Catapulted 35%, Pulling Insmed, Liquidia With It
The company sells Tyvaso, a treatment for lung diseases. On Tuesday, Tyvaso showed promise, again, in a chronic condition. 
Via Investor's Business Daily
Tuesday's pre-market session: top gainers and losers
As we await the opening of the US market on Tuesday, let's delve into the pre-market session and discover the top gainers and losers shaping the early market sentiment. 
Via Chartmill
12 Health Care Stocks Moving In Tuesday's Pre-Market Session
 
Via Benzinga
United Therapeutics Corp. (NASDAQ:UTHR) Embodies Peter Lynch's GARP Strategy
United Therapeutics (UTHR) exemplifies Peter Lynch's GARP strategy with strong EPS growth, zero debt, and an undervalued PEG ratio. A model for long-term investors. 
Via Chartmill
2 Mid-Cap Stocks with Competitive Advantages and 1 Facing Headwinds
Many investors pay attention to mid-cap stocks because they have established business models and expansive market opportunities. However, their paths to becoming $100 billion corporations are ripe with... 
Via StockStory
3 Market-Beating Stocks to Consider Right Now
The best-performing stocks typically have robust sales growth, increasing margins, and rising returns on capital, and those that can maintain this trifecta year in and year out often become the legends... 
Via StockStory
2 Profitable Stocks to Keep an Eye On and 1 That Underwhelm
Even if a company is profitable, it doesn’t always mean it’s a great investment. Some struggle to maintain growth, face looming threats, or fail to reinvest wisely, limiting their future potential. 
Via StockStory
< Previous 1 2 3 4 5 6 7 8 9 10 Next >
Stock Quote API & Stock News API supplied by www.cloudquote.io
Quotes delayed at least 20 minutes.
By accessing this page, you agree to the Privacy Policy and Terms Of Service.
© 2025 FinancialContent. All rights reserved.